Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
May 7, 2015 4:06 PM EDT
ANN ARBOR, MI -- (Marketwired) -- 05/07/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 (bempedoic acid) development program updates and financial results for the first quarter ended March 31, 2015.
"Esperion had another truly transformational quarter," said Tim M. Mayleben, president and chief executive officer of Esperion. "Following the recently announced positive Phase 2b add-on to statin clinical study results of ETC-1002, we are actively... More
